Oracle Health Sciences applications has been chosen by DreamCIS, a contract research organization in Korea. DreamCIS required a clinical trial management system to replace its legacy clinical software solution and help enable the company’s biometrics center to become an Asian clinical trial data management hub.
DreamCIS intends to use Oracle Clinical and Oracle Remote Data Capture (RDC) 4.5.3 to help meet global standards for clinical trials data management and achieve higher quality local clinical trial services. DreamCIS is the first CRO in Korea to adopt the applications.
“Oracle’s proven experience in the health sciences sector was important to us and we believe their solutions will enable us to raise our data management levels to global standards, and help us become the leader in the Asian clinical trial markets in the future,” said Hee-Joong Koh, Director, Biometrics Center, DreamCIS.
Oracle RDC 4.5.3 uses the same data model as Oracle Clinical, ensuring tight integration of data between these applications. It is also completely Web-based, with a ‘zero client footprint’ for the HTML data entry window. This enables improved global access and performance for life sciences organizations to conduct global clinical studies more cost effectively whether using traditional pen and paper, electronic data capture, or hybrid methods.
“As the number of clinical trials increases in the Korean market and throughout Asia, there is a growing need for best-in-class software applications for clinical development and drug safety,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We are committed to helping emerging CROs like DreamCIS accelerate insights for better health and look forward to supporting their efforts to become an important hub for clinical data management in the region.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.